These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6292610)

  • 21. Solubilization and preliminary characterization of mu and kappa opiate receptor subtypes from rat brain.
    Chow T; Zukin RS
    Mol Pharmacol; 1983 Sep; 24(2):203-12. PubMed ID: 6310362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative analysis of multiple kappa-opioid receptors by selective and nonselective ligand binding in guinea pig spinal cord: resolution of high and low affinity states of the kappa 2 receptors by a computerized model-fitting technique.
    Tiberi M; Magnan J
    Mol Pharmacol; 1990 May; 37(5):694-703. PubMed ID: 2160061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of tifluadom on passive avoidance behaviour in DBA/2 mice.
    Pavone F; Castellano C
    Behav Brain Res; 1985 May; 15(3):177-81. PubMed ID: 2988580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Agonist and antagonist activity of kappa opioids in the squirrel monkey: II. Effect of chronic morphine treatment.
    Craft RM; Dykstra LA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):334-42. PubMed ID: 1309877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The kappa opioid receptor and food intake.
    Morley JE; Levine AS; Kneip J; Grace M; Zeugner H; Shearman GT
    Eur J Pharmacol; 1985 May; 112(1):17-25. PubMed ID: 2990965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
    Picker MJ; Dykstra LA
    J Pharmacol Exp Ther; 1989 May; 249(2):557-66. PubMed ID: 2566680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological profile of various kappa-agonists at kappa-, mu- and delta-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the rat brain.
    Mulder AH; Burger DM; Wardeh G; Hogenboom F; Frankhuyzen AL
    Br J Pharmacol; 1991 Feb; 102(2):518-22. PubMed ID: 1673074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tifluadom-induced diuresis in rats. Evidence for an opioid receptor-mediated central action.
    Shearman GT; Tolcsvai L
    Neuropharmacology; 1986 Aug; 25(8):853-6. PubMed ID: 3022178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic.
    De Souza EB; Schmidt WK; Kuhar MJ
    J Pharmacol Exp Ther; 1988 Jan; 244(1):391-402. PubMed ID: 2826773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tifluadom (KC 5103) induces suppression and latency changes on somatosensory evoked potentials which are reversed by opioid antagonists.
    Freye E; Hartung E; Schenk GK
    Life Sci; 1983; 33 Suppl 1():537-40. PubMed ID: 6319908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output.
    Craft RM; Dykstra LA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):327-33. PubMed ID: 1309876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential antagonism of bremazocine- and U69,593-induced antinociception by quadazocine: further functional evidence of opioid kappa receptor multiplicity in the mouse.
    Horan PJ; de Costa BR; Rice K; Haaseth RC; Hruby VJ; Porreca F
    J Pharmacol Exp Ther; 1993 Aug; 266(2):926-33. PubMed ID: 8394923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of mu and kappa opioid receptor agonists on rat plasma corticosterone levels.
    Hayes AG; Stewart BR
    Eur J Pharmacol; 1985 Oct; 116(1-2):75-9. PubMed ID: 2996912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irreversible selective blockade of kappa-opioid receptors in the guinea-pig ileum.
    Sheehan MJ; Hayes AG; Tyers MB
    Eur J Pharmacol; 1986 Sep; 129(1-2):19-24. PubMed ID: 3021476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The kappa opioid receptor, ingestive behaviors and the obese mouse (ob/ob).
    Morley JE; Levine AS; Gosnell BA; Kneip J; Grace M
    Physiol Behav; 1983 Nov; 31(5):603-6. PubMed ID: 6320237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Demonstration of the heterogeneity of the kappa-opioid receptors in guinea-pig cerebellum using selective and nonselective drugs.
    Tiberi M; Magnan J
    Eur J Pharmacol; 1990 Jun; 188(6):379-89. PubMed ID: 2164939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profile of activity of kappa receptor agonists in the rabbit vas deferens.
    Hayes A; Kelly A
    Eur J Pharmacol; 1985 Apr; 110(3):317-22. PubMed ID: 2988982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple opiate binding sites in the central nervous system of the rabbit. Large predominance of a mu subtype in the cerebellum and characterization of a kappa subtype in the thalamus.
    Meunier JC; Kouakou Y; Puget A; Moisand C
    Mol Pharmacol; 1983 Jul; 24(1):23-9. PubMed ID: 6306437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. P-7521--a new irreversible opioid ligand.
    Jin WQ; Fan LQ; Chen XJ; Chi ZQ
    Zhongguo Yao Li Xue Bao; 1989 May; 10(3):205-10. PubMed ID: 2558497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of levorphanol and several kappa-selective opioids on respiration and behavior in rhesus monkeys.
    Howell LL; Bergman J; Morse WH
    J Pharmacol Exp Ther; 1988 Apr; 245(1):364-72. PubMed ID: 2834543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.